Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes

Tariq Shafi, Tammy L. Sirich, Timothy W. Meyer, Thomas H. Hostetter, Natalie S. Plummer, Seungyoung Hwang, Michal L. Melamed, Tanushree Banerjee, Josef Coresh, Neil R. Powe

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - 2017

Fingerprint

Indican
Renal Dialysis
Sudden Cardiac Death
Serum Albumin
Cardiovascular Diseases
Demography
4-cresol sulfate
Confidence Intervals
Mortality

Keywords

  • Cardiovascular mortality
  • Dialysis outcomes
  • Hippurate
  • Indoxyl sulfate
  • P-cresol sulfate
  • Phenylacetylglutamine

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Shafi, T., Sirich, T. L., Meyer, T. W., Hostetter, T. H., Plummer, N. S., Hwang, S., ... Powe, N. R. (Accepted/In press). Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney International. https://doi.org/10.1016/j.kint.2017.05.012

Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. / Shafi, Tariq; Sirich, Tammy L.; Meyer, Timothy W.; Hostetter, Thomas H.; Plummer, Natalie S.; Hwang, Seungyoung; Melamed, Michal L.; Banerjee, Tanushree; Coresh, Josef; Powe, Neil R.

In: Kidney International, 2017.

Research output: Contribution to journalArticle

Shafi, Tariq ; Sirich, Tammy L. ; Meyer, Timothy W. ; Hostetter, Thomas H. ; Plummer, Natalie S. ; Hwang, Seungyoung ; Melamed, Michal L. ; Banerjee, Tanushree ; Coresh, Josef ; Powe, Neil R. / Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. In: Kidney International. 2017.
@article{a1fffbe8fd5b4611ac7c367d6f9ecd99,
title = "Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes",
abstract = "Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63{\%} were Black and 42{\%} were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12{\%} higher risk of cardiac death (hazard ratio 1.12; 95{\%} confidence interval, 0.98-1.27) and 22{\%} higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22{\%} of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.",
keywords = "Cardiovascular mortality, Dialysis outcomes, Hippurate, Indoxyl sulfate, P-cresol sulfate, Phenylacetylglutamine",
author = "Tariq Shafi and Sirich, {Tammy L.} and Meyer, {Timothy W.} and Hostetter, {Thomas H.} and Plummer, {Natalie S.} and Seungyoung Hwang and Melamed, {Michal L.} and Tanushree Banerjee and Josef Coresh and Powe, {Neil R.}",
year = "2017",
doi = "10.1016/j.kint.2017.05.012",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes

AU - Shafi, Tariq

AU - Sirich, Tammy L.

AU - Meyer, Timothy W.

AU - Hostetter, Thomas H.

AU - Plummer, Natalie S.

AU - Hwang, Seungyoung

AU - Melamed, Michal L.

AU - Banerjee, Tanushree

AU - Coresh, Josef

AU - Powe, Neil R.

PY - 2017

Y1 - 2017

N2 - Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.

AB - Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.

KW - Cardiovascular mortality

KW - Dialysis outcomes

KW - Hippurate

KW - Indoxyl sulfate

KW - P-cresol sulfate

KW - Phenylacetylglutamine

UR - http://www.scopus.com/inward/record.url?scp=85025143240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025143240&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.05.012

DO - 10.1016/j.kint.2017.05.012

M3 - Article

C2 - 28739139

AN - SCOPUS:85025143240

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -